EGFR and glioma: Indeed, there is preclinical evidence for the immunogenicity of a number of neo-epitopes arising from hallmark glioma mutations, including EGFRvIII (an intragenic deletion of exons 2–7 of the epidermal growth factor receptor), IDH1R132H and H3.3K27M 35–37.